News

When PBS Biotech needed to scale its single-use bioreactor systems from research laboratories to commercial manufacturing, the company turned to a partner with deep expertise in industrial automation: rockwell Automation. The collaboration, announced September 29, 2026, represents a convergence of two industries that historically operated in separate spheres—biotechnology and industrial control systems.

PBS Biotech's challenge was not uncommon in the biopharmaceutical sector. The company had developed sophisticated bioreactor technology capable of producing cell therapies at scale, but translating laboratory protocols into reproducible manufacturing processes required automation expertise beyond the biotech domain. Cell therapy manufacturing demands precise control over temperature, pH, dissolved oxygen, and agitation rates—parameters that must remain within tight tolerances across multiple production batches.

Rockwell Automation's role extends beyond simply providing programmable logic controllers and supervisory control systems. The partnership involves standardizing automation architectures that can be deployed across PBS Biotech's global customer base. This standardization addresses a critical pain point in biomanufacturing: the difficulty of transferring processes between facilities while maintaining consistent product quality.

The biotechnology industry has traditionally relied on custom-built control systems, often developed in-house by engineering teams with specialized knowledge of biological processes. While this approach offers flexibility, it creates challenges when scaling production or transferring technology to contract manufacturing organizations. Rockwell's standardized platforms promise to reduce these barriers by providing a common automation foundation that can be adapted to specific process requirements without requiring complete redesign.

Time-to-results acceleration represents another key benefit of the partnership. Cell therapy development timelines directly impact patient access to treatments. By reducing the time required to establish robust manufacturing processes, the collaboration could shorten the path from laboratory discovery to clinical application. Rockwell's experience in rapid deployment and commissioning of industrial systems brings methodologies that biotechnology companies are increasingly adopting.

The partnership also highlights the growing importance of data integrity in biomanufacturing. Regulatory agencies require comprehensive documentation of manufacturing parameters and process deviations. Rockwell's automation platforms include built-in data collection and reporting capabilities that help PBS Biotech meet these requirements while providing insights for process optimization.

For industrial automation suppliers, the biotechnology sector represents a growing market opportunity. The industry's emphasis on quality, traceability, and regulatory compliance creates demand for sophisticated control systems that can provide detailed audit trails and support validation activities. Companies that can demonstrate understanding of bioprocess requirements while delivering reliable automation solutions will find increasing demand.

The collaboration between PBS Biotech and Rockwell Automation also reflects broader trends in industry convergence. Technologies developed for one sector increasingly find applications in others. Industrial IoT platforms, predictive maintenance algorithms, and advanced process control techniques originally developed for chemical manufacturing or oil refining now benefit biotechnology companies seeking to improve yields and reduce costs.

Control system architecture in biomanufacturing differs from traditional industrial applications in several important ways. The need for single-use equipment compatibility, strict hygiene requirements, and flexible batch sizing creates unique design challenges. Rockwell's experience across multiple industries provides PBS Biotech with access to best practices that might not be available from biotech-focused automation suppliers alone.

The partnership's emphasis on Rockwell automation platforms means that PBS Biotech's customers can leverage a common control environment regardless of their facility location or local engineering resources. This consistency reduces training requirements and simplifies troubleshooting when issues arise. For companies operating multiple manufacturing sites or working with contract manufacturers, such standardization provides significant operational advantages.

Looking forward, similar partnerships between automation suppliers and biotechnology companies are likely to increase. The biopharmaceutical industry faces pressure to reduce manufacturing costs while maintaining quality standards. Industrial automation techniques offer proven solutions for achieving these goals, but successful implementation requires collaboration between domain experts from both fields.

The Rockwell automation platform brings decades of experience in industrial control to the biotechnology sector. PBS Biotech contributes deep understanding of cell culture processes and regulatory requirements. Together, they represent a model for how cross-industry collaboration can accelerate innovation in sectors where traditional approaches have reached their limits.

For automation engineers considering opportunities in biotechnology, this partnership illustrates the value of adaptable skills. The fundamental principles of process control remain constant across industries, but successful application requires understanding the specific requirements and constraints of each domain. Engineers who can bridge these gaps will find increasing demand as industries continue to converge.

The success of this collaboration will likely be measured not just in technical achievements but in patient outcomes. Faster development of cell therapies, more consistent manufacturing quality, and reduced costs all contribute to making advanced treatments more accessible. In this context, industrial automation becomes not just a technical discipline but a contributor to healthcare advancement.

Written by: Maxwell, a senior automation engineer with over 15 years of experience in process control and biotechnology manufacturing. Maxwell has worked on automation projects across multiple industries and understands the unique challenges of applying industrial control techniques to biological processes.